Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorundrostat (Primary)
  • Indications Cardiovascular disorders; Hypertension
  • Focus Adverse reactions; First in man
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 06 Mar 2023 Results of a first-in-human trial of MLS-101, a novel small molecule inhibitor with CYP11B2 selectivity presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
    • 20 Feb 2023 According to a Mineralys Therapeutics media release, data from this study will be presented at the American College of Cardiologys 72nd Annual Scientific Session together with the World Congress of Cardiology (ACC.23/WCC).
    • 08 Apr 2021 Results published in the Mitsubishi Tanabe Pharma Corporation media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top